Table 1.
Baseline Clinical Characteristics of Subjects of the %ΔAd Subgroups and Endpoint Ad Subgroups
| %ΔAd Subgroups |
Endpoint Ad Subgroups |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| All | Decreased Group | ≥21.5% Group | 21.4%–9.3% Group | 9.1%–0.0% Group | P Value (ANOVA) | >5.2 μg/mL | ≤5.2 μg/mL | P Valuea | |
| n | 1698 | 544 | 382 | 384 | 388 | 404 | 1294 | ||
| Age, y | 49 ± 10 | 48 ± 10 | 50 ± 10 | 50 ± 10 | 49 ± 10 | 0.037 | 51 ± 10 | 49 ± 10 | 0.002 |
| BMI, kg/m2 | 24.6 ± 2.9 | 24.6 ± 2.8 | 24.8 ± 3.0 | 24.7 ± 3.0 | 24.5 ± 2.9 | 0.693 | 24.5 ± 3.0 | 24.7 ± 2.9 | 0.213 |
| BW, kg | 72.0 ± 10.3 | 71.7 ± 9.4 | 72.7 ± 11.2 | 72.4 ± 10.6 | 71.5 ± 10.2 | 0.710 | 72.1 ± 11.1 | 72.0 ± 10.0 | 0.803 |
| WC, cm | 87.9 ± 7.7 | 87.6 ± 7.5 | 88.7 ± 8.2 | 88.1 ± 7.6 | 87.5 ± 7.3 | 0.258 | 88.0 ± 8.0 | 87.9 ± 7.6 | 0.838 |
| SBP, mm Hg | 126 ± 14 | 125 ± 15 | 127 ± 15 | 125 ± 13 | 125 ± 13 | 0.152 | 127 ± 14 | 126 ± 14 | 0.055 |
| DBP, mm Hg | 79 ± 9 | 79 ± 10 | 80 ± 10 | 79 ± 10 | 79 ± 9 | 0.153 | 80 ± 10 | 79 ± 9 | 0.013 |
| Total cholesterol, mg/dL | 213 ± 33 | 216 ± 34 | 210 ± 33 | 210 ± 32 | 212 ± 32 | 0.074 | 209 ± 31 | 214 ± 33 | 0.041 |
| HDL cholesterol, mg/dL | 53 ± 12 | 54 ± 12 | 53 ± 13 | 54 ± 12 | 53 ± 10 | 0.440 | 54 ± 12 | 53 ± 12 | 0.722 |
| LDL cholesterol, mg/dL | 132 ± 31 | 134 ± 31 | 129 ± 30 | 131 ± 30 | 133 ± 31 | 0.185 | 131 ± 30 | 133 ± 31 | 0.486 |
| TG, mg/dL | 176 ± 135 | 184 ± 135 | 180 ± 158 | 169 ± 129 | 169 ± 114 | 0.100 | 160 ± 106 | 182 ± 143 | 0.001 |
| UA, mg/dL | 6.5 ± 1.2 | 6.5 ± 1.2 | 6.5 ± 1.2 | 6.4 ± 1.2 | 6.5 ± 1.2 | 0.339 | 6.4 ± 1.1 | 6.5 ± 1.2 | 0.222 |
| FPG, mg/dL | 97 ± 9 | 97 ± 9 | 97 ± 9 | 97 ± 10 | 97 ± 9 | 0.955 | 97 ± 9 | 97 ± 10 | 0.892 |
| HbA1c, % | 5.2 ± 0.4 | 5.3 ± 0.4 | 5.2 ± 0.4 | 5.3 ± 0.4 | 5.3 ± 0.4 | 0.451 | 5.2 ± 0.4 | 5.3 ± 0.4 | 0.056 |
| Cr, mg/dL | 0.83 ± 0.13 | 0.83 ± 0.13 | 0.84 ± 0.16 | 0.84 ± 0.13 | 0.83 ± 0.12 | 0.476 | 0.83 ± 0.13 | 0.83 ± 0.13 | 0.750 |
| HOMA-IR | 1.9 ± 1.1 | 1.9 ± 1.1 | 2.0 ± 1.2 | 1.9 ± 1.2 | 1.8 ± 1.0 | 0.521 | 1.8 ± 1.0 | 2.0 ± 1.1 | 0.003 |
| F-IRI. μU/mL | 7.9 ± 4.4 | 8.0 ± 4.1 | 8.1 ± 4.9 | 7.9 ± 4.5 | 7.6 ± 4.0 | 0.370 | 7.4 ± 4.2 | 8.1 ± 4.4 | 0.003 |
| Baseline Ad, μg/mL | 4.1 ± 0.8 | 4.2 ± 0.8 | 4.1 ± 0.8b | 4.0 ± 0.8b | 4.2 ± 0.7 | <0.001 | 4.7 ± 0.4 | 4.0 ± 0.8 | <0.001 |
| Ad at endpoint, μg/mL | 4.5 ± 1.2 | 3.8 ± 0.8 | 5.7 ± 1.4b | 4.6 ± 0.9b | 4.4 ± 0.8b | <0.001 | 6.2 ± 0.9 | 4.0 ± 0.8 | <0.001 |
| %ΔAd, % | 9.7 ± 22.4 | −11.4 ± 8.0 | 40.4 ± 22.1b | 15.1 ± 3.5b | 3.8 ± 3.0b | <0.001 | 31.9 ± 25.6 | 2.8 ± 16.0 | <0.001 |
| %ΔBW, % | −0.5 ± 4.8 | 1.5 ± 4.2 | −3.8 ± 5.6b | −0.9 ± 4.2b | 0.4 ± 3.7b | <0.001 | −2.8 ± 5.7 | 0.2 ± 4.3 | <0.001 |
| %ΔBMI, % | −0.2 ± 4.8 | 1.6 ± 4.2 | −3.4 ± 5.6b | −0.6 ± 4.2b | 0.6 ± 3.7b | <0.001 | −2.4 ± 5.6 | 0.4 ± 4.3 | <0.001 |
| %ΔWC, % | −0.4 ± 4.7 | 1.2 ± 4.2 | −3.1 ± 5.3b | −0.7 ± 4.3b | 0.4 ± 4.0b | <0.001 | −2.3 ± 5.4 | 0.2 ± 4.3 | <0.001 |
| Family history of diabetes, n (%) | 412 (24.2) | 143 (26.3) | 96 (25.1) | 74 (19.3) | 99 (25.5) | 0.075 | 85(21.0) | 327 (25.3) | 0.083 |
Abbreviations: ANOVA, analysis of variance; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; TG, triglyceride; %ΔAd, percent change in serum adiponectin; %ΔBW, percent change in body weight; %ΔWC, percent change in waist circumference.
Data are mean ± standard deviation or number of subjects.
a
P < 0.05 compared with the decreased group by the Mann-Whitney U test.
b
P < 0.05 compared with the decreased group by post hoc multiple comparisons (Turkey test).